Study of Combination Therapy With SYR-322

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

NCT01318070 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan

NCT01263496 ·Status: COMPLETED ·Phase: PHASE2

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

NCT00286442 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

NCT01289119 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

NCT01263483 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00286494 ·Status: COMPLETED ·Phase: PHASE3

Double-blind Comparative Study of SYR-472

NCT01632007 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

NCT01263470 ·Status: COMPLETED ·Phase: PHASE2

Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

NCT01263509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

NCT02068443 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.

NCT00755846 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

NCT00286455 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.

NCT00655863 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00328627 ·Status: COMPLETED ·Phase: PHASE3

A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

NCT01686711 ·Status: COMPLETED ·Phase: PHASE4

SYR-472 Open-label Study

NCT01751360 ·Status: COMPLETED ·Phase: PHASE3

Long-term Study of SYR-472

NCT01431807 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00432276 ·Status: COMPLETED ·Phase: PHASE3

Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

NCT01318135 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

NCT01777282 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

NCT00763347 ·Status: TERMINATED ·Phase: PHASE2

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

NCT00395512 ·Status: COMPLETED ·Phase: PHASE3

A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

NCT02324569 ·Status: COMPLETED ·Phase: PHASE3

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

NCT01945216 ·Status: COMPLETED